Feasibility & Effect of a Tele-rehabilitation Program in Pulmonary Sarcoidosis Pulmonary Sarcoidosis
Launched by AARHUS UNIVERSITY HOSPITAL · Apr 11, 2019
Trial Information
Current as of July 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at a new way to help people with pulmonary sarcoidosis, a condition that affects the lungs and can make it hard to breathe. The study will test a tele-rehabilitation program, which means patients will receive physical therapy and support through video calls and online sessions instead of in-person visits. This approach aims to help patients improve their lung function and overall health, especially those who live far from healthcare facilities.
To participate in the trial, individuals must be at least 18 years old and have a confirmed diagnosis of pulmonary sarcoidosis. They also need to have certain lung function levels and be able to walk a minimum distance. Participants will be divided into two groups: one will take part in the tele-rehabilitation program for 12 weeks, while the other will continue with regular check-ups. Throughout the study, both groups will be monitored to see how their lung function, physical abilities, anxiety levels, and quality of life change over time. This trial is an important step in finding effective ways to support patients with pulmonary sarcoidosis, especially those who might struggle to access traditional rehabilitation programs.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Diagnosis of PS
- • Signed informed consent
- • Adults ≥ 18 years
- • DLCO ≥ 30% predicted and FVC ≥ 50% predicted
- • 6 minute walking test distance ≥ 150 m
- Exclusion Criteria:
- • Participation in an official rehabilitation program \< 3 months before start of the study Musculoskeletal disorders
- • Severe cardiac diseases (ejection fraction \< 30%, daily angina, or otherwise specified by treating cardiologist)
- • Unable to understand informed consent
- • Other conditions that hamper the use of tele-rehabilitation
- • Non-Danish speaking.
- • Unwillingness to implement the protocol
About Aarhus University Hospital
Aarhus University Hospital is a leading research institution in Denmark, dedicated to advancing medical science and improving patient care through innovative clinical trials. As a key sponsor of clinical research, the hospital integrates cutting-edge technology and multidisciplinary expertise to conduct studies that address critical health challenges. With a commitment to ethical standards and patient safety, Aarhus University Hospital collaborates with a diverse network of academic and industry partners, ensuring that its research initiatives contribute to the global body of medical knowledge and enhance treatment options for patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
århus, Aarhus, Denmark
Patients applied
Trial Officials
Elisabeth Bendstrup, PhD, MD
Principal Investigator
Aarhus University Hospital
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials